Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Enekinragene Inzadenovec
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pacira to Present 104-Week Data on PCRX-201 in Knee Osteoarthritis
Details : PCRX-201 (enekinragene inzadenovec) is an IL-1 receptor inhibitor gene therapy candidate, which is currently being evaluated for the treatment of osteoarthritis of the knee.
Product Name : PCRX-201
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 22, 2025
Lead Product(s) : Enekinragene Inzadenovec
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Enekinragene Inzadenovec
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pacira Presents 104-Week Safety and Efficacy Data of PCRX-201 for Osteoarthritis
Details : PCRX-201 (enekinragene inzadenovec), is a adenoviral gene therapy vector codes for IL-1Ra expression, which is being evaluated for moderate to severe osteoarthritis of the knee.
Product Name : PCRX-201
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 26, 2024
Lead Product(s) : Enekinragene Inzadenovec
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bupivacaine
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Premier
Deal Size : Undisclosed
Deal Type : Agreement
Pacira BioSciences Awarded Brand Pharmaceuticals Agreement with Premier, Inc.
Details : Through the agreement, Premier will have access of EXPAREL (bupivacaine), a single-dose regional analgesic that provides prolonged postsurgical pain control while reducing reliance on opioids.
Product Name : Exparel
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 02, 2024
Lead Product(s) : Bupivacaine
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Premier
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Enekinragene Inzadenovec
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pacira Announces RMAT Designation for PCRX-201 in Osteoarthritis Treatment
Details : PCRX-201 (enekinragene inzadenovec) is a high-capacity gene therapy vector coding for IL-1Ra to block inflammation in osteoarthritis and disease progression.
Product Name : PCRX-201
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 13, 2024
Lead Product(s) : Enekinragene Inzadenovec
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bupivacaine
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EXPAREL® (bupivacaine liposome injectable suspension) expand label to include administration in adults as an adductor canal block and a sciatic nerve block in the popliteal fossa.
Product Name : Exparel
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 11, 2023
Lead Product(s) : Bupivacaine
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bupivacaine
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Second Phase 3 study of EXPAREL (bupivacaine) achieves primary and key secondary endpoints; safely demonstrating statistically significant reductions in postsurgical pain and opioid consumption through 96 hours.
Product Name : Exparel
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 22, 2022
Lead Product(s) : Bupivacaine
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bupivacaine
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EXPAREL achieved the study’s primary endpoint demonstrating a statistically significant reduction in cumulative pain scores from 0 to 96 hours compared with bupivacaine HCl (p<0.01).
Product Name : Exparel
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 09, 2022
Lead Product(s) : Bupivacaine
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Triamcinolone Acetonide
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Pacira BioSciences
Deal Size : Undisclosed
Deal Type : Acquisition
Details : This acquisition is a major milestone to build a robust offering of novel, non-opioid treatments to improve patient care along the neural pain pathway while simultaneously providing a complementary commercial asset in ZILRETTA for the treatment of OA kne...
Product Name : Zilretta
Product Type : Hormone
Upfront Cash : Undisclosed
November 10, 2021
Lead Product(s) : Triamcinolone Acetonide
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Pacira BioSciences
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Bupivacaine
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Eurofarma Laboratorios S.A
Deal Size : Undisclosed
Deal Type : Agreement
Pacira BioSciences Signs Exparel Distribution Agreement With Eurofarma in Latin America
Details : Under the terms of the agreement, Eurofarma obtains the exclusive right to market and distribute EXPAREL in 19 countries in Latin America, including Argentina, Brazil, Colombia, and Mexico.
Product Name : Exparel
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 22, 2021
Lead Product(s) : Bupivacaine
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Eurofarma Laboratorios S.A
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Humantakinogene Hadenovec
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Company to expand FX201 low dose and mid dose cohorts to include up to 20 additional patients in each treatment group. Clinical data from the first two cohorts indicate that FX201 appears to be generally safe and well-tolerated at the low and mid doses.
Product Name : FX201
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 18, 2021
Lead Product(s) : Humantakinogene Hadenovec
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable